Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
The duration of the study period for each participant was up to 13 weeks, including a screening period up to 5 days, and 12-week follow-up after the injection.
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Moderate to severe pain due to non-traumatic vertebral fracture associated with osteoporosis.
You may not be if
Mild pain score on the Pain Intensity-Numeric Rating Scale \[PI-NRS\] at screening and randomization visits;
Narcotic addiction;
Post-fracture vertebral instability;
Unwillingness to use study-defined rescue analgesia exclusively.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain
